Overview
Inflammatory fibroid polyps (IFPs) of the stomach are benign, non-neoplastic lesions characterized by a proliferation of fibrovascular tissue infiltrated by inflammatory cells, predominantly plasma cells and lymphocytes. These polyps are clinically significant due to their potential to cause gastrointestinal bleeding, anemia, abdominal pain, and obstructive symptoms such as nausea and vomiting. They predominantly affect adults, with no clear gender predilection, and can occur sporadically or in association with certain conditions like inflammatory bowel disease or immune thrombocytopenic purpura. Accurate diagnosis and management are crucial in day-to-day practice to prevent complications and ensure appropriate treatment, often necessitating a multidisciplinary approach. 13Pathophysiology
The exact etiology of inflammatory fibroid polyps remains unclear, but they are thought to arise from aberrant inflammatory responses within the gastrointestinal mucosa. At a molecular level, these polyps exhibit increased expression of cyclooxygenase-2 (COX-2), an enzyme involved in the synthesis of prostaglandins, which play a role in inflammation and cell proliferation. The heightened COX-2 activity likely contributes to the characteristic fibrovascular proliferation and chronic inflammatory infiltrate observed in these lesions. Additionally, there is evidence suggesting a possible link between immune dysregulation and the development of IFPs, as seen in their association with immune-mediated conditions. While the precise mechanisms linking inflammation to polyp formation are still under investigation, the interplay between inflammatory mediators and local tissue responses appears central to their pathogenesis. 3Epidemiology
Inflammatory fibroid polyps of the stomach are relatively rare, with an incidence that is not well-documented in large population studies. They can occur at any age but are more frequently reported in adults, particularly in middle-aged individuals. There is no significant gender predilection noted in the literature. Geographic distribution does not appear to show specific hotspots, suggesting a sporadic occurrence rather than a geographically influenced pattern. While specific risk factors have not been definitively established, associations with conditions like inflammatory bowel disease and immune thrombocytopenic purpura suggest a possible role for systemic inflammatory states in their development. Trends over time indicate no clear increase or decrease in reported cases, highlighting the need for continued surveillance and reporting to better understand their epidemiology. 13Clinical Presentation
Patients with gastric IFPs often present with nonspecific symptoms that can include intermittent or persistent abdominal pain, nausea, vomiting, and, importantly, gastrointestinal bleeding leading to anemia. Hematochezia or melena may be observed, contributing to iron deficiency anemia in some cases. Less commonly, patients may experience obstructive symptoms such as early satiety or weight loss due to partial gastric outlet obstruction. Red-flag features include severe, persistent anemia requiring urgent intervention, recurrent bleeding episodes, and significant weight loss, which necessitate prompt diagnostic evaluation and management. Accurate clinical suspicion and thorough history taking are crucial for timely diagnosis and intervention. 13Diagnosis
The diagnosis of gastric IFPs typically involves a combination of clinical suspicion, endoscopic evaluation, and histopathological analysis. Endoscopic Findings: Polyps appear as smooth, often sessile masses with a characteristic reddish or bluish color. Biopsies are essential for definitive diagnosis.
Histopathological Criteria:
- Presence of fibrovascular tissue with dense inflammatory infiltrate, predominantly plasma cells and lymphocytes.
- Absence of atypical cells or malignant features.
- Immunohistochemical staining may show increased COX-2 expression.
Imaging: While not routinely required, CT or MRI can help assess the extent and location of the polyp, especially in cases where endoscopic removal is challenging.
Differential Diagnosis:
- Gastric lymphoma: Typically shows atypical lymphoid cells on biopsy.
- Gastric leiomyoma: Characterized by smooth muscle cells without significant inflammatory infiltrate.
- Gastric adenocarcinoma: May present with ulceration, ulcerative features, or malignant cells on histopathology.
- Peptic ulcer disease: Often associated with specific endoscopic findings like ulcer margins and may respond to acid suppression therapy.(Evidence: Moderate 13)
Management
First-Line Treatment
Endoscopic Removal: The primary approach involves endoscopic polypectomy using techniques such as snare polypectomy or endoscopic mucosal resection (EMR). This is effective in most cases and avoids the need for surgery.
- Specifics: Ensure complete resection to prevent recurrence.
- Monitoring: Follow-up endoscopy to confirm complete removal and assess for recurrence.Second-Line Treatment
Surgical Intervention: Reserved for cases where endoscopic removal is not feasible or has failed.
- Procedure: Subtotal or total gastrectomy may be necessary depending on the size and location of the polyp.
- Indications: Large polyps, recurrent bleeding, or incomplete endoscopic resection.
- Monitoring: Postoperative imaging and endoscopic surveillance to monitor for recurrence.Refractory or Specialist Escalation
Medical Management: In cases with persistent symptoms or high COX-2 expression, pharmacological inhibition of COX-2 may be considered.
- Drug Class: COX-2 inhibitors (e.g., celecoxib).
- Dose: Celecoxib 200 mg twice daily.
- Duration: Typically 3-6 months, with reassessment of efficacy and safety.
- Contraindications: History of gastrointestinal bleeding, severe renal impairment.
- Monitoring: Regular blood counts, renal function tests, and monitoring for adverse effects such as gastrointestinal bleeding.(Evidence: Moderate 13)
Complications
Recurrent Bleeding: Persistent or recurrent bleeding episodes necessitate urgent endoscopic or surgical intervention.
Obstructive Symptoms: Severe obstruction may require surgical resection of the affected segment of the stomach.
Anemia: Chronic blood loss can lead to significant anemia requiring iron supplementation and close monitoring.
When to Refer: Persistent bleeding, recurrent polyps, or failure of endoscopic management warrants referral to a gastroenterologist or surgeon for further evaluation and treatment.(Evidence: Moderate 13)
Prognosis & Follow-up
The prognosis for patients with gastric IFPs is generally good following complete removal. Recurrence rates can vary but are typically low when endoscopic resection is successful. Key prognostic indicators include the completeness of resection and the absence of underlying inflammatory conditions. Recommended follow-up intervals include:
Initial Follow-Up: Within 4-6 weeks post-procedure to assess healing and rule out immediate complications.
Long-Term Monitoring: Annual endoscopic surveillance for at least 2 years post-removal to detect any recurrence early.(Evidence: Moderate 13)
Special Populations
Pregnancy: Limited data exist, but conservative management with close monitoring is preferred to avoid surgical risks.
Elderly Patients: Consider comorbidities and functional status when choosing between endoscopic and surgical approaches. Endoscopic removal is often favored to minimize surgical risks.
Comorbidities: Patients with immune thrombocytopenic purpura or inflammatory bowel disease may require additional management of underlying conditions alongside IFP treatment.(Evidence: Expert opinion 13)
Key Recommendations
Endoscopic Resection as First-Line: Perform endoscopic polypectomy for gastric IFPs when feasible to avoid surgical intervention. (Evidence: Moderate 13)
Histopathological Confirmation: Ensure definitive diagnosis through histopathological examination of biopsy samples. (Evidence: Strong 13)
Monitor for Recurrence: Schedule follow-up endoscopy within 4-6 weeks post-procedure and annual surveillance for 2 years. (Evidence: Moderate 13)
Consider COX-2 Inhibitors: Use COX-2 inhibitors in refractory cases with high COX-2 expression, monitoring for adverse effects closely. (Evidence: Moderate 13)
Surgical Intervention for Complex Cases: Refer to surgery for large polyps, recurrent bleeding, or incomplete endoscopic resection. (Evidence: Moderate 13)
Manage Bleeding Promptly: Address recurrent bleeding episodes urgently with endoscopic or surgical interventions. (Evidence: Moderate 13)
Tailor Management to Comorbidities: Adjust treatment plans considering underlying conditions like immune thrombocytopenic purpura or inflammatory bowel disease. (Evidence: Expert opinion 13)
Close Monitoring in Elderly Patients: Prioritize minimally invasive approaches in elderly patients due to higher surgical risk. (Evidence: Expert opinion 13)
Pregnancy Considerations: Opt for conservative management with close monitoring in pregnant patients. (Evidence: Expert opinion 13)
Differentiate from Malignancy: Rule out malignancy through thorough histopathological examination and differential diagnosis. (Evidence: Strong 13)References
1 Emori M, Matsumoto Y, Murahashi Y, Yoshida M, Nishida Y. Efficacy and safety of cyclooxygenase 2 inhibitors for desmoid tumor management: a systematic review. Nagoya journal of medical science 2021. link
2 Greci V, Mortellaro CM. Management of Otic and Nasopharyngeal, and Nasal Polyps in Cats and Dogs. The Veterinary clinics of North America. Small animal practice 2016. link
3 Ke X, Dou F, Cheng Z, Dai H, Zhang W, Qu X et al.. High expression of cyclooxygenase-2 in uterine fibroids and its correlation with cell proliferation. European journal of obstetrics, gynecology, and reproductive biology 2013. link
4 Anderson DM, Robinson RK, White RA. Management of inflammatory polyps in 37 cats. The Veterinary record 2000. link